Disease-Modifying drugs for multiple sclerosis in pregnancy; A systematic review

Neurology

Volumn 79, Issue 11, 2012, Pages 1130-1135

  Lu, Ellen ^a   Wang, Bing Wei ^a   Guimond, Colleen ^a   Synnes, Anne ^a   Sadovnick, Dessa ^a   Tremlett, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FINGOLIMOD; GLATIRAMER; MITOXANTRONE; NATALIZUMAB;

ARTICLE; BIRTH WEIGHT; CESAREAN SECTION; COHORT ANALYSIS; CONGENITAL MALFORMATION; DRUG SAFETY; GESTATIONAL AGE; HUMAN; LOW BIRTH WEIGHT; MULTIPLE SCLEROSIS; PERINATAL DEVELOPMENT; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROGENY; PROSPECTIVE STUDY; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW;

EID: 84867560628     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182698c64     Document Type: Article

References (37)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-1517.
2. Freedman MS, Hughes B, Mikol DD, et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: A systematic comparison. Eur Neurol 2008;60:1-11.
3. Martindale: The Complete Drug Reference, 35th ed. London: Pharmaceutical Press; 2008.
4. Hellwig K, Brune N, Haghikia A, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008;118:24-28.
5. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-29.
6. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: A prospective observational study. Mult Scler 2009;15:1037-1042.
7. Teva Pharmaceuticals. Copaxone (glatiramer acetate) [online]. Available at: www.copaxone.com/pdf/prescribinginformation.pdf. Accessed March 14, 2010.
8. US Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling [online]. Available at: Edocket.access.gpo.gov/2008/pdf/E8- 11806.pdf. Accessed March 14, 2010.
9. Biogen Idec. Avonex (interferon beta-1a) [online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2007/103628s5115lbl.pdf. Accessed March 14, 2010.
10. Bayer HealthCare. Betaseron (interferon beta-1b) [online]. Available at: Berlex.bayerhealthcare.com/html/products/pi/Betaseron-PI.pdf. Accessed March 14, 2010.
11. Biogen Idec/Elan Pharmaceuticals I. Tysabri (natalizumab) [online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2006/125104s015lbl. pdf. Accessed March 14, 2010.
12. Novartis Pharmaceuticals Corp. Gilenya (fingolimod) [online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2010/022527s000lbl.pdf. Accessed March 14, 2010.
13. EMD Serono I/C. Novantrone (mitoxantrone) [online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2009/019297s030s031lbl.pdf. Accessed March 14, 2010.
14. Sayre MR, O'Connor RE, Atkins DL, et al. Part 2: Evidence evaluation and management of potential or perceived conflicts of interest: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010;122:S657-S664.
15. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62: 1013-1020.
16. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. Neurology 2005;65:807-811.
17. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011;17:958-963.
18. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010;75:1794-1802.
19. Fernandez Liguori N, Klajn D, Acion L, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult Scler 2009;15:555-562.
20. Lu E, Dahlgren L, Sadovnick D, Sayao A, Synnes A, Tremlett H. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult Scler 2012;18:460-467.
21. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2010;257:580-583.
22. Patti F, Cavallaro T, Lo Fermo S, et al. Is in utero earlyexposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 2008;255:1250-1253.
23. De Las Heras V, De Andres C, Tellez N, et al. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: A descriptive study in the Spanish population. Mult Scler 2007;13:981-984.
24. Fragoso YD, Finkelsztejn A, Comini-Frota ER, et al. Pregnancy and multiple sclerosis: The initial results from a Brazilian database. Arq Neuropsiquiatr 2009;67:657-660.
25. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: A retrospective, multicentre case series. CNS Drugs 2010;24:969-976.
26. Finkelsztejn A, Fragoso YD, Ferreira ML, et al. The Brazilian database on pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2011;113:277-280.
27. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: Preliminary safety and birth outcomes. J Neurol 2011;257:2020-2023.
28. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon -1a in patients with multiple sclerosis. Neurology 2005;65:802-806.
29. Sandberg-Wollheim M, Alteri E, Stam Moraga M, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011;17:423-430.
30. Lowry RB. Congenital anomalies surveillance in Canada. Can J Public Health 2008;99:483-485.
31. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. Fetal growth and development. In: Williams Obstetrics, 23 ed. New York: McGraw-Hill; 2010.
32. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis. Mult Scler 2011;17(suppl 10): S303. Abstract.
33. Hellwig K, Haghikia A, Gold R. Multiple sclerosis and pregnancy experience from a nationwide database. Neurology 2011;76(suppl 4):A273. Abstract.
34. Foulds P, Richman S, Glick G, Onigman T, Hyde R. Pregnancy outcomes from the Avonex® (interferon beta-1a) pregnancy exposure registry. Mult Scler 2010;16(suppl 10): S315. Abstract.
35. Miller AE, Reardon JL. Use of glatiramer acetate during pregnancy: Offering women a choice. Neurology 2010; 74(suppl 2):A554. Abstract.
36. Cristiano LM, Bozic C, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry. Mult Scler 2011; 17(suppl 10):S457. Abstract.
37. Collins W, Francis G, Koren G, et al. Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Neurology 2011;76(suppl 4):A609. Abstract.